MarketFriction

Bliss GVS Pharma Ltd

NSE BLISSGVS · BSE 506197 · Pharmaceuticals
₹683.60 -1.56%
NSE close2026-10-01
52 week range118.00 - 739.90
Market cap₹7,559 Cr.
P/E54.9
ASM long-term Price band 5%

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Consolidated, Rs crore
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales212201198184218210198207244218257286
Expenses158157170149176181177166201183213209
Operating Profit544428344130214143354476
OPM %26%22%14%19%19%14%11%20%18%16%17%27%
Other Income135-24451512358161110
Interest122241253121
Depreciation6777788888910
Profit before tax5940-4303636236341414575
Tax %27%27%24%26%28%29%29%30%30%39%18%32%
Net Profit4329-5222626174429253751
EPS in Rs4.052.64-0.871.972.312.261.474.082.582.203.364.72
Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales5477988158996895777477527708109271,005
Expenses391596618739566471629634620683760806
Operating Profit156203197160123107118117151127168199
OPM %29%25%24%18%18%18%16%16%20%16%18%20%
Other Income2412-8352620-4218-0366745
Interest19202348651078127
Depreciation13202191317171926293335
Profit before tax14817514518212910454106117126190202
Tax %32%36%39%30%26%29%57%28%30%28%29%
Net Profit10011389127957423778290135142
EPS in Rs8.007.955.7011.999.436.641.456.807.218.0012.2112.86
Dividend Payout %6%8%18%8%5%8%34%7%7%6%4%
10 Years5 Years3 YearsTTM1 YearLast Year
Compounded Sales Growth5%10%7%21%
Compounded Profit Growth5%14%23%29%
Stock Price CAGR18%45%100%366%
Return on Equity11%9%10%12%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital101010101010101010101111
Reserves3274024765266367257988088739571,0401,182
Borrowings1601322251181021261221091021008822
Other Liabilities166218311206157168147181171145163278
Total Liabilities6627621,0238609051,0301,0771,1091,1571,2121,3011,492
Fixed Assets234225305143146242234281379370406459
CWIP094047022238216
Investments000000028445
Other Assets4285277147177127888408037688308711,022
Total Assets6627621,0238609051,0301,0771,1091,1571,2121,3011,492
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity381132891840476413534103106139
Cash from Investing Activity-29-50-24948-79-40-45-103-6-83-75-38
Cash from Financing Activity-42-40-10-7617-6-21-24-25-21-30-89
Net Cash Flow-342330-10-220-293-1011
Free Cash Flow5101186-72-125563-59753384
CFO/OP45%101%160%29%-8%69%87%143%67%91%112%108%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days222201116134187290293192187192198204
Inventory Days69555055466411011694113111129
Days Payable165153100554775828679586389
Cash Conversion Cycle12610267134186279321221202247246244
Working Capital Days10584-10135154232264179192207198214
ROCE %23%31%29%27%26%18%12%14%12%14%12%17%
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters35.06%34.97%34.97%34.90%34.82%35.10%35.29%35.44%35.39%35.36%35.36%35.01%
FIIs16.31%15.35%14.74%13.24%12.13%13.51%13.18%12.65%13.27%14.54%10.45%8.07%
DIIs6.61%6.60%6.59%6.58%6.56%6.55%6.55%6.54%5.98%5.78%5.04%9.46%
Public42.00%43.08%43.71%45.27%46.49%44.84%44.98%45.37%45.36%44.32%49.15%47.45%
No. of Shareholders43,23440,75845,15744,73752,93749,55849,51746,70744,46143,38044,87446,767

Fundamentals

Market Cap₹ 7,559 Cr.
Current Price₹ 711
Stock P/E54.9
Book Value₹ 113
ROCE16.9 %
ROE11.8 %
Dividend Yield0.21 %
Face Value₹ 1.00
Compounded Sales Growth (TTM)21%
Compounded Profit Growth (TTM)29%
Consolidated figures.
Valuation
Market capRs 7,232 Cr
Enterprise valueRs 7,087 Cr
P/E (TTM)53.10x
Price to book6.06x
Price to sales7.19x
EV / EBITDA29.01x
EV / EBIT33.89x
EV / sales7.05x
Price to cash flow52.13x
Earnings yield1.88%
Dividend yield0.07%
P/E, 3-year average16.01x
P/B, 3-year average1.44x
P/E, 5-year average22.33x
P/B, 5-year average1.23x
Profitability
Operating margin (excl. other income)18.08%
Operating margin (incl. other income)25.36%
EBITDA margin24.30%
Pre-tax margin20.09%
Net profit margin13.55%
Net margin, latest quarter17.54%
ROE11.51%
ROCE17.13%
ROA9.24%
ROE, 3-year average9.34%
ROCE, 3-year average13.77%
ROA, 3-year average7.44%
ROE, 5-year average7.64%
ROCE, 5-year average11.97%
ROA, 5-year average5.99%
ROIC (approx.)14.18%
Tax rate28.94%
Other income / net worth5.66%
Growth
Sales growth (latest year)14.50%
Profit growth (latest year)53.18%
Sales CAGR, 3 years7.25%
Sales CAGR, 5 years9.94%
Profit CAGR, 3 years22.14%
Profit CAGR, 5 years13.52%
Sales growth QoQ11.12%
Profit growth QoQ40.81%
Sales growth YoY (latest quarter)37.65%
Profit growth YoY (latest quarter)16.40%
Per share
EPS (TTM)Rs 12.87
EPS (latest year)Rs 12.21
EPS (latest quarter)Rs 4.74
EPS, 3-year averageRs 9.14
EPS, 5-year averageRs 7.13
Book value per shareRs 112.76
Sales per shareRs 95.02
Cash flow per shareRs 13.11
Free cash flow per shareRs 7.94
Dividend per share (latest year)Rs 0.50
Dividend per share, 3-year averageRs 0.50
Dividend per share, 5-year averageRs 0.50
Dividends
Dividend payout4.10%
Dividend payout, 3-year average5.76%
Dividend payout, 5-year average11.82%
Efficiency
Asset turnover0.62x
Fixed asset turnover2.02x
Inventory turnover3.07x
Inventory days119 days
Debtor days204 days
Debtors turnover1.79x
Creditor days89 days
Cash conversion cycle244 days
Working capital days214 days
Leverage
Total debtRs 22 Cr
Cash and bankRs 167 Cr
Net debtRs -145 Cr
Debt to equity0.02x
Net debt / EBITDA-0.59x
Interest coverage29.37x
Current ratio (filing 2026-03-31)4.02x
Quick ratio (filing 2026-03-31)3.38x
Trade payables (filing 2026-03-31)Rs 104 Cr
Owners' fund to total sources79.93%
Debt to assets1.46%
Cash flow
Cash from Operating Activity (latest year)Rs 139 Cr
Cash from Investing Activity (latest year)Rs -38 Cr
Cash from Financing Activity (latest year)Rs -89 Cr
Net Cash Flow (latest year)Rs 11 Cr
Free cash flow (latest year)Rs 84 Cr
FCFE (approx.: FCF + change in debt)Rs 18 Cr
Cash from ops / profit, 5 years1.27x
Sales to cash flow6.68x
Statement figures
Net sales (TTM)Rs 1,005 Cr
Net sales (latest year)Rs 927 Cr
Sales (latest quarter)Rs 286 Cr
Operating profit excl. other income (latest year)Rs 168 Cr
Operating profit (latest quarter)Rs 76 Cr
Other income (TTM)Rs 45 Cr
EBITDA (TTM)Rs 244 Cr
PBDT (TTM)Rs 237 Cr
Profit before tax (TTM)Rs 202 Cr
Tax (latest year)Rs 55 Cr
Net profit (TTM)Rs 136 Cr
Net profit (latest year)Rs 129 Cr
Net profit (latest quarter)Rs 50 Cr
Depreciation (TTM)Rs 35 Cr
Depreciation (latest quarter)Rs 10 Cr
Interest (TTM)Rs 7 Cr
Cost of goods sold (latest year)Rs 462 Cr
Total expenditure (latest year)Rs 760 Cr
Total income (latest year)Rs 995 Cr
Share capitalRs 11 Cr
ReservesRs 1,182 Cr
Shareholders' fundsRs 1,193 Cr
Total assetsRs 1,492 Cr
Net blockRs 459 Cr
Capital work in progressRs 6 Cr
InvestmentsRs 5 Cr
ReceivablesRs 517 Cr
InventoryRs 151 Cr
Other liabilitiesRs 278 Cr
Shares outstanding (crore)10.58
Ownership
Promoter holding35.01% (-0.43 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
P/E 53.1 is at the 92th percentile of its own 9.4-year range (median 19.0, low 8.0, high 56.0).
P/B 6.06 is at the 98th percentile (median 1.64).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
PeriodBLISSGVSNifty 50Difference
1 week-0.5%-2.8% +2.3 pts
1 month+8.4%-6.8% +15.2 pts
3 months+35.1%-7.6% +42.7 pts
6 months+217.1%+0.4% +216.7 pts
1 year+363.1%-9.9% +373.0 pts
2 years+402.9%-13.6% +416.4 pts
3 years+666.8%+14.2% +652.6 pts
5 years+524.0%+27.9% +496.1 pts
2 mutual fund schemes hold about ₹0 Cr. Over three months 0 bought more and 0 sold (share counts, price move removed).
FundWeightEst. Cr3m shares
Bandhan BSE Healthcare Index Fund0.25%0
Union Active Momentum Fund0.00%0

Red flags

F-score 7 of 8
lookOn NSE surveillance On NSE surveillance: ASM long-term
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Latest quarter

Jun 2026
Sales ₹286 Cr +38.2% vs Jun 2025. Net profit ₹51 Cr +15.9%.

Activity

Compare
CompanyMcap (Cr)P/EROCE
Sun Pharmaceutical Industries Ltd447,47635.420.5 %
Divis Laboratories Ltd250,36384.022.0 %
Torrent Pharmaceuticals Ltd186,15283.415.2 %
Zydus Lifesciences Ltd119,75024.621.1 %
Cipla Ltd111,43031.115.5 %
Laurus Labs Ltd106,92897.817.8 %
Mankind Pharma Ltd105,12049.313.5 %
Dr Reddys Laboratories Ltd104,49432.413.0 %
Aurobindo Pharma Ltd97,68225.812.9 %
Lupin Ltd93,84015.829.9 %
Glenmark Pharmaceuticals Ltd68,90522.139.8 %
Alkem Laboratories Ltd62,77227.621.2 %
Biocon Ltd61,43984.53.61 %
Abbott India Ltd57,94935.944.8 %
Gland Pharma Ltd49,33343.115.1 %
DateClientSideQtyPrice
2026-09-28Anupam Rasayan India LimitedBUY2,250,000723.29
Ex-dateActionFactor
2026-07-08Dividend - Re 1 Per Share
2026-02-18Interim Dividend - Re 0.50 Per Share
2025-07-24Annual General Meeting/Dividend - Rs 0.50 Per Share
2024-07-18Annual General Meeting/Dividend - Rs 0.50 Per Share
2023-07-12Annual General Meeting/Dividend - Re 0.50 Per Share
2022-06-20Annual General Meeting/ Dividend - Rs 0.50 Per Share
2021-09-13 Annual General Meeting/Dividend - Rs 0.50 Per Share
2020-09-17 Annual General Meeting/Dividend - Rs 0.50 Per Share
2019-09-12 Annual General Meeting/Dividend - Re 1 Per Share
2018-08-14 Annual General Meeting/Dividend- Re 1 Per Share
2017-09-18 Annual General Meeting/Dividend - Re 0.60 Per Share (Book Closure Dates Revised)
2016-09-06 Annual General Meeting/Dividend Re 0.50 Per Share
2015-09-08Annual General Meeting/ Dividend - Re 0.50/- Per Share (Book Closure Dates Revised)
2015-02-24Interim Dividend - Re 0.20 Per Share
2014-08-13Annual General Meeting / Final Dividend - Re 0.50/- Per Share
2013-08-01Annual General Meeting / Dividend Rs 0.40 Per Share
2013-02-25Interim Dividend Rs 0.30 Per Share
2012-08-02Annual General Meeting / Dividend Rs 0.40 Per Share
2011-11-24Interim Dividend Re.0.35 Per Share
2011-07-14Dividend-Re.0.30 Per Share
2010-11-25Interim Dividend Re 0.30 Per Share
DateTypeWhat it says
2026-10-01Board meeting outcomeOutcome of Board Meeting held on October 01, 2026.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Long Term Additional Surveillance Measure (Long Term ASM): stage 4Scrip PE is greater than 50 (4 trailing quarters)
Data: NSE and BSE daily reports, company filings. Numbers only, not investment advice, not a SEBI-registered research service.Updated 2026-10-03